Skip to Main content Skip to Navigation
Journal articles

Title: Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?: MHT and breast cancer according to timing of treatment initiation

Abstract : PURPOSE To investigate whether the relation between estrogen-progestagen menopausal hormone therapy (EP-MHT) and breast cancer risk varies according to the delay between menopause onset and treatment initiation. MATERIALS AND METHODS Between 1992 and 2005, 1,726 invasive breast cancers were identified among 53,310 postmenopausal women from the French E3N cohort (mean duration of follow-up: 8.1 years). Hazard ratios (HRs) and confidence intervals (CI) were estimated using Cox models, with MHT never-users as the reference. RESULTS Among recent users of EP-MHT, the risk of breast cancer varied according to the timing of treatment initiation. This variation was confined to short durations of use (≤2 years): the HR was 1.54 (95% CI 1.28-1.86) for short treatments initiated in the 3-year period following menopause onset and 1.00 (95% CI 0.68-1.47) for short treatments initiated later (p=0.04 for homogeneity). This pattern of risks was however not observed in users of EP-MHT containing progesterone, among whom there was no significantly increased risk associated with short durations of use (HR 0.87, 95% CI 0.57-1.32 for treatments initiated ≤3 years after menopause and 0.90, 95% CI 0.45-1.81 for treatments initiated later). Longer durations of EP-MHT use were generally associated with increases in breast cancer risk, whatever the gap time. CONCLUSION Our results suggest that, for some EP-MHT, the timing of treatment initiation transiently modulates the risk of breast cancer; and that, when initiated close to menopause, even short durations of use are associated with an increased breast cancer risk. Estrogen-progesterone combinations might be an exception in this regard.
Complete list of metadatas

Cited literature [4 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01319999
Contributor : Agnès Fournier <>
Submitted on : Monday, May 23, 2016 - 12:58:36 PM
Last modification on : Friday, October 23, 2020 - 5:01:46 PM

Files

Article seconde révision_HAL....
Files produced by the author(s)

Identifiers

Citation

Agnès Fournier, Sylvie Mesrine, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon. Title: Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?: MHT and breast cancer according to timing of treatment initiation. Journal of Clinical Oncology, American Society of Clinical Oncology, 2009, 27 (31), pp.5138-43. ⟨10.1200/JCO.2008.21.6432⟩. ⟨inserm-01319999⟩

Share

Metrics

Record views

648

Files downloads

934